研究者業績

鍋島 俊隆

ナベシマ トシタカ  (Toshitaka Nabeshima)

基本情報

所属
藤田医科大学 大学院医療科学研究科 客員教授 (名古屋大学名誉教授)
NPO 医薬品適正使用推進機構 理事長
学位
薬学博士(東北大学)

J-GLOBAL ID
201101030936121945
researchmap会員ID
B000004803

外部リンク

藤田医科大学大学院医療科学研究科 客員教授
学歴
1968年3月岐阜薬科大学製薬学科卒業
1973年3月大阪大学大学院薬学研究科博士課程単位取得後中退
1977年12月東北大学にて博士号修得(薬学)
職歴
1973年 4月名城大学薬学部 助手
1978年10月~1981年5月米国ミシシッピー州立大学メディカルセンター 客員助教授
1982年 4月名城大学薬学部 講師
1984年 4月名城大学薬学部 助教授
1990年 1月名古屋大学大学院医学系研究科臨床情報学講座医療薬学分野・医学部附属病院薬剤部 教授・部長(併任)
2006年 1月特定非営利活動法人医薬品適正使用推進機構理事長
2007年 3月名古屋大学を定年退職
2007年 4月より名城大学大学院薬学研究科 薬品作用学研究室 教授
2012年 3月名城大学を定年退職
2012年 4月より名城大学薬学部寄附講座 地域医療薬局学講座特任教授
2015年 3月より名城大学薬学部 特任教授
2015年12月より藤田医科大学大学院保健学研究科(現 医療科学研究科) 客員教授
現在の主な研究分野:神経精神薬理学:精神疾患動物モデルの作成と新薬開発への応用、薬物依存、医薬品の適正使用についての研究


論文

 794
  • Wenjun Zhu, Akira Sobue, Rinako Tanaka, Kazuhiro Hada, Daisuke Ibi, Yue Liu, Tetsuo Matsuzaki, Taku Nagai, Toshitaka Nabeshima, Kozo Kaibuchi, Norio Ozaki, Hiroyuki Mizoguchi, Hiroaki Ikesue, Kiyofumi Yamada
    Behavioural Brain Research 496 115832-115832 2026年1月  
  • Takatoshi Sakata, Kazuo Kunisawa, Masaya Hasegawa, Yumiko Seto, Aoi Ogawa, Hitomi Kurahashi, Yasuko Yamamoto, Masao Takemura, Hidetoshi Matunami, Tomoya Sugai, Noriki Kutsumura, Kuniaki Saito, Toshitaka Nabeshima, Akihiro Mouri
    British Journal of Pharmacology 2025年12月21日  
    Abstract Background and Purpose Lifestyle is closely related to major depressive disorder (MDD). Given the growing focus on the impact of diet on mental health, this study examined how dietary habits affect the pathophysiology of MDD. Experimental Approach Health check‐up data were analysed. Mice received sucrose under chronic unpredictable mild stress (CUMS) and were evaluated by behavioural, neurochemical and metabolic analysis. Key Results Health check‐up data showed increased sucrose intake in MDD patients. When mice received sucrose under CUMS, hyperactivity and aggression were attenuated, although social deficits or behavioural despair induced by CUMS persisted, and recognition memory was impaired. The behavioural changes were associated with dysfunction of the locus coeruleus‐prefrontal cortex circuit, caused by impaired noradrenaline release due to presynaptic α 2 ‐adrenoceptor upregulation, and postsynaptic α 1 ‐adrenoceptor and β 1 ‐adrenoceptor downregulation. α 2 ‐Adrenoceptor antagonism by atipamezole rescued behavioural changes induced by sucrose intake under CUMS, whereas α 2 ‐adrenoceptor agonism by guanfacine in CUMS mice mimicked these behavioural changes. Among the antidepressants, mirtazapine effectively increased noradrenaline release and rescued behavioural changes induced by sucrose intake under CUMS. Sucrose intake under CUMS induced peripheral hyperglycaemia and dysregulation of central glucose metabolism. Glucose transporter inhibition by phloretin rescued behavioural changes induced by sucrose intake under CUMS. Intracerebroventricular and systemic streptozotocin administration reproduced these behavioural changes and α 2 ‐adrenoceptor upregulation. Conclusions and Implications Our findings suggest that the observed behavioural changes are associated with dysfunction of the noradrenergic α 2 ‐adrenoceptor system induced by impaired glucose metabolism. These insights targeting the noradrenergic‐metabolic axis might be a new strategy for sugar‐induced depression subtypes.
  • Moeka Tanabe, Kazuo Kunisawa, Tadashi Fujii, Takumi Tochio, Yoshiki Hirooka, Haruto Ojika, Yuta Naruoka, Hiroyasu Ito, Kuniaki Saito, Toshitaka Nabeshima, Akihiro Mouri
    Journal of Neurochemistry 169(11) 2025年11月20日  
    ABSTRACT Psychiatric disorders such as major depressive disorder are closely linked to the intestinal environment, suggesting intestinal health may contribute to their prevention. Prebiotics, which enhance intestinal health, are promising candidates for preventing psychiatric disorders. 1‐Kestose (kestose), a type of prebiotics, has shown potential, but its effects on psychiatric disorders remain unclear. In this study, we investigated whether kestose prevents abnormal behaviors induced by social isolation (SI) stress and which underlies mechanisms of preventive effects. C57BL/6J male mice (3 weeks old) were divided into two groups: individually housed (SI) group and housed five mice per cage (GH) group. Each group received either a normal diet or a kestose diet (5% kestose) for 5 weeks daily until the end of the behavioral testing. Kestose prevented the SI‐induced abnormal behaviors including reduced sociality, impaired spatial recognition, and heightened anxiety, which were associated with suppressed microglial activation in the hippocampus. Kestose altered the diversity of gut microbiota and increased the abundance of Bacteroides sartorii . Furthermore, short‐chain fatty acids (SCFAs) such as butyric acid, acetic acid, and propionic acid, produced by intestinal microbiota, were increased after kestose supplementation. Positive correlations were observed between B. sartorii abundance and SCFA levels, suggesting that B. sartorii contributes to SCFA production. Notably, both B. sartorii and SCFAs were strongly associated with the abnormal behaviors by SI. These findings suggest that kestose prevents SI‐induced abnormal behaviors by modulating gut microbiota, particularly B. sartorii , through an increase of SCFA production. Taken together, kestose could be used as a promising prebiotic intervention for psychiatric disorders. image
  • Youyun Zhu, Kanako Kitagawa, Daisuke Mori, Tetsuo Matsuzaki, Taku Nagai, Toshitaka Nabeshima, Sayaka Takemoto-Kimura, Hiroaki Ikesue, Norio Ozaki, Hiroyuki Mizoguchi, Kiyofumi Yamada
    European Journal of Pharmacology 178407-178407 2025年11月  
  • Geyao Dong, Daisuke Mori, Tetsuo Matsuzaki, Rinako Tanaka, Norimichi Itoh, Takaaki Matsui, Ayato Sato, Yuko Arioka, Hiroki Okumura, Ryota Fukaya, Hiroshi Kuba, Taku Nagai, Toshitaka Nabeshima, Hiroaki Ikesue, Takao Kohno, Mitsuharu Hattori, Kozo Kaibuchi, Norio Ozaki, Hiroyuki Mizoguchi, Kiyofumi Yamada
    Pharmacological Research 221 107986-107986 2025年11月  

MISC

 950

書籍等出版物

 14
  • 吉尾 隆, 鍋島俊隆, 渡辺泰裕, 早勢伸正, 賀川義之, 大井一弥, 丸山 徹, 渡辺朋子, 野田幸裕, 本屋敏郎, 松尾和廣, 髙村徳人, 唯野貢司, 加藤裕芳 (担当:共編者(共編著者))
    南山堂 2018年3月20日 (ISBN: 4525720573)
  • 吉尾 隆, 鍋島俊隆, 渡辺泰裕, 早勢伸正, 賀川義之, 大井一弥, 丸山 徹, 渡辺朋子, 野田幸裕, 本屋敏郎, 松尾和廣, 髙村徳人, 唯野貢司, 加藤裕芳 (担当:共編者(共編著者))
    南山堂 2017年3月14日 (ISBN: 4525720565)
  • 鍋島 俊隆, 井上 和秀 (担当:共編者(共編著者))
    南山堂 2015年9月28日 (ISBN: 9784525720612)
  • 鍋島 俊隆, 名城大学薬学部地域医療薬局学講座, 特任教授, NPO 法人, 医薬品適正使用推進機構, 長, 杉浦 伸一, 学大学院医学系研究科特任研究部門医療行政学, 特任准教授
    じほう 2015年5月7日 (ISBN: 4840746273)
  • 鍋島 俊隆 (担当:単訳) (原著:Array)
    星和書店 2011年5月14日 (ISBN: 4791107713)

講演・口頭発表等

 13

共同研究・競争的資金等の研究課題

 40